Age-Specific Risk of High-Grade Cervical Lesions in Unvaccinated Women: Implications for HPV Screening Policies in Low-Vaccination Settings
Diagnostics, cilt.16, sa.5, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 16 Sayı: 5
- Basım Tarihi: 2026
- Doi Numarası: 10.3390/diagnostics16050659
- Dergi Adı: Diagnostics
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, Directory of Open Access Journals, Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO)
- Anahtar Kelimeler: cervical intraepithelial neoplasia (CIN2+), cervical screening, cytology, high-risk HPV, HPV persistence, HPV vaccination, unvaccinated women
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Background: In Turkey, where HPV vaccination is not yet routinely implemented, cervical cancer screening with primary HPV testing begins at age 30. This may result in undetected high-grade cervical lesions in younger unvaccinated women. The aim of this study was to evaluate the age-specific prevalence of CIN2+ lesions, HPV persistence, and the diagnostic performance of cytology among women under 30. Methods: A retrospective cohort study was conducted in 689 unvaccinated women aged 18–30 who underwent colposcopy following a positive high-risk HPV (hrHPV) test. Participants were stratified into two groups: 18–24 and 25–30 years. HPV genotypes, 12-month persistence, cytological findings, and biopsy-confirmed histopathology were analyzed using logistic regression and ROC curve analysis. Results: CIN2+ lesions were identified in 17.5% of women aged 18–24 and 44.9% of those aged 25–30 (p < 0.001). Persistent HPV 16 infection was the strongest predictor of CIN2+. Cytology showed low sensitivity in detecting CIN2+ (36.4% and 47.2% in the respective age groups). ROC analysis revealed better model performance in older women (AUC 0.81 vs. 0.73, p = 0.047). Conclusions: A significant proportion of unvaccinated women aged 25–30 harbor undiagnosed CIN2+ lesions. These findings support lowering the age of HPV-based screening to 25 in low-vaccination settings. Cytology alone is insufficient as a triage tool in this population.